Capital Research Global Investors boosted its position in athenahealth, Inc. (NASDAQ:ATHN) by 15.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,041,714 shares of the health services provider’s stock after purchasing an additional 273,660 shares during the period. Capital Research Global Investors owned 5.11% of athenahealth worth $286,963,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. FMR LLC raised its position in athenahealth by 0.8% in the second quarter. FMR LLC now owns 5,975,119 shares of the health services provider’s stock valued at $839,803,000 after purchasing an additional 47,341 shares during the last quarter. Morgan Stanley grew its holdings in shares of athenahealth by 9.7% during the first quarter. Morgan Stanley now owns 4,514,305 shares of the health services provider’s stock worth $508,717,000 after purchasing an additional 397,837 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of athenahealth by 1.8% during the second quarter. Vanguard Group Inc. now owns 3,100,643 shares of the health services provider’s stock worth $435,795,000 after purchasing an additional 53,361 shares during the last quarter. BlackRock Inc. grew its holdings in shares of athenahealth by 2.0% during the second quarter. BlackRock Inc. now owns 1,631,993 shares of the health services provider’s stock worth $229,377,000 after purchasing an additional 32,146 shares during the last quarter. Finally, Clearbridge Investments LLC grew its holdings in shares of athenahealth by 61.8% during the first quarter. Clearbridge Investments LLC now owns 908,505 shares of the health services provider’s stock worth $102,379,000 after purchasing an additional 347,133 shares during the last quarter.

athenahealth, Inc. (ATHN) traded down 1.20% during trading on Wednesday, reaching $122.03. The company’s stock had a trading volume of 50,803 shares. athenahealth, Inc. has a one year low of $90.11 and a one year high of $158.66. The company has a 50-day moving average of $132.79 and a 200 day moving average of $129.75. The firm has a market cap of $4.87 billion, a PE ratio of 154.86 and a beta of 1.76.

athenahealth (NASDAQ:ATHN) last announced its quarterly earnings data on Thursday, July 20th. The health services provider reported $0.51 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.39 by $0.12. athenahealth had a net margin of 2.80% and a return on equity of 6.91%. The business had revenue of $301.10 million for the quarter, compared to analysts’ expectations of $298.68 million. During the same quarter in the prior year, the company earned $0.34 earnings per share. The business’s revenue was up 15.0% compared to the same quarter last year. Analysts expect that athenahealth, Inc. will post $1.91 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Capital Research Global Investors Raises Position in athenahealth, Inc. (ATHN)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/04/capital-research-global-investors-raises-position-in-athenahealth-inc-athn.html.

Several research analysts have recently issued reports on the company. Royal Bank Of Canada assumed coverage on athenahealth in a research note on Tuesday, September 19th. They issued a “sector perform” rating and a $153.00 price objective for the company. KeyCorp reiterated a “buy” rating and set a $170.00 target price on shares of athenahealth in a research report on Sunday, September 17th. Jefferies Group LLC reduced their target price on shares of athenahealth from $135.00 to $120.00 and set a “hold” rating on the stock in a report on Friday, September 15th. Robert W. Baird reissued a “buy” rating and set a $170.00 target price on shares of athenahealth in a report on Thursday, August 31st. Finally, Morgan Stanley reissued an “equal weight” rating and set a $125.00 target price (up from $108.00) on shares of athenahealth in a report on Wednesday, August 2nd. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and twelve have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $149.91.

In other news, Director Brandon H. Hull sold 800 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $140.01, for a total value of $112,008.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jonathan Bush sold 4,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $124.17, for a total value of $496,680.00. Following the completion of the sale, the chief executive officer now directly owns 319,807 shares in the company, valued at $39,710,435.19. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,505 shares of company stock worth $2,240,851. Insiders own 3.20% of the company’s stock.

athenahealth Company Profile

athenahealth, Inc provides network-based medical record, revenue cycle, patient engagement, care coordination and population health services. The Company also offers Epocrates and other point-of-care mobile applications. The Company delivers majority of its service offerings through a single instance of cloud-based software, athenaNet.

Want to see what other hedge funds are holding ATHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for athenahealth, Inc. (NASDAQ:ATHN).

Institutional Ownership by Quarter for athenahealth (NASDAQ:ATHN)

Receive News & Stock Ratings for athenahealth Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for athenahealth Inc. and related stocks with our FREE daily email newsletter.